Table of Contents
NEW YORK — Leading bioinformatics software company Qlucore has agreed a two-year license with the large pharmaceutical company Boehringer Ingelheim worth approximately 1.67 million SEK. As a leading pharmaceutical company engaged in research and development across multiple locations worldwide and a previous customer of Qlucore, the license enables global utilization of Qlucore Omics Explorer software.
Carl-Johan Ivarsson
Qlucore Omics Explorer is software designed for research in pharmaceuticals and biotechnology, catering to both commercial and academic users. Through interactive visualization coupled with rapid calculations, users can identify crucial information within often vast and complex datasets. The software is currently utilized by researchers in over 200 organizations across more than 20 countries, to publish over 1000 scientific articles.
“We are extremely proud that Boehringer Ingelheim has once again chosen to order Qlucore Omics Explorer licenses for use in their research and development,” says Carl-Johan Ivarsson, CEO of Qlucore.
